Search results
Results from the WOW.Com Content Network
Tablet: 200 mg, 400 mg, 600 mg: UK [1] EmuProfen: USA Espidifen: Spain Eve: Japan Faspic: Tablet: 200 mg, 400 mg: Philippines Fenbid: Topical gel: 10%: China, UK [1] Fenpaed: Oral liquid: 20 mg/mL: UK, New Zealand [14] Feverfen: Oral liquid: 100 mg/5 mL: UK [1] Finalflex: Slovenia Galprofen: UK [citation needed] Gelofen: Iran Genpril: USA [3 ...
Flurbiprofen is a member of the phenylalkanoic acid derivative family of nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain.
1.name 2.age 3.sex 4.occupation 5.address 6.chief complaint of patient 7.history of patient:- present illness history past illness history medical history family history personal history 8.pain site of pain nature of pain quantity of pain on v.a.s scale type of pain 9.examination active movement passive movement 10.observation gait posture r.o ...
The R&D group at teva api consists of a team of over 760 top scientists located in 7 development centers worldwide: A large center in Israel (synthetic products and peptides), a large center in Hungary (fermentation and semi-synthetic products), and a facility in India and additional sites in Italy, Croatia, Mexico and the Czech Republic (development of high potency API). teva api's R&D ...
Kaye built Norton Healthcare Ltd., a UK generic pharmaceutical company, which was acquired by Ivax Corporation in 1990. [2] He became chairman of Ivax Pharmaceuticals UK. In 2006 Ivax was sold to Teva Pharmaceuticals for $7.4 billion. [2] In 2002 Ivax was the largest supplier of generic drugs to the NHS. [1]
Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women". [2] In India it is marketed under the brand name of Ibset. It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow. [3] [4] and in India as Ibset.
The most common adverse events for patients receiving Cal/BD were pruritus (3.1%), headache (2.8%), and nasopharyngitis (2.3%). Lesional/perilesional adverse events, defined as an adverse event located ≤2 cm from the lesional border, were reported by 8.7% of patients treated with Cal/BD ointment.
Cladribine tablets are administered as 2 courses separated by 1 year (a maximum of 20 days of treatment). The recommended cumulative dose is 3.5 mg/kg weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.